An executive summary of the report on the PAN Foundation roundtable, presented with The American Journal of Managed Care, discussed the shift from the problem of the "uninsured" to the "underinsured."
Advocacy groups and foundations play a role in helping patients meet new cost-sharing challenges in healthcare, but they cannot provide a long-term solution by themselves, according to a report on the roundtable hosted earlier this year by the Patient Access Network (PAN) Foundation, in collaboration with The American Journal of Managed Care (AJMC).
The PAN Foundation and AJMC presented Cost Sharing Roundtable: Improving Access to Critical Therapies on February 26, 2016, which featured national experts from advocacy groups, academia, insurers, and the pharmaceutical industry on the shifting challenges of helping patients afford drugs as prices rise and the nature of the problem changes.
The Affordable Care Act (ACA) has brought coverage to millions—the Obama Administration states 20 million now have it because of the law. But, as an executive summary to the 60-page report states, the problem has shifted from the “uninsured” to the “underinsured.” Many beneficiaries of modest means have plans that feature low premiums, but their out-of-pocket costs are crippling in the event of a major illness.
The problem, as this report and other research has found, is that the ACA plans appeal to the most-price sensitive Americans, and many do not understand how to evaluate a plan based on value. When those with chronic disease or cancer have a plan requiring high co-payments or co-insurance, the executive summary states, “it causes the greatest hardship for the most vulnerable population.”
The summary discusses the challenges associated with “specialty tier” medications, for diseases like cancer and hepatitis C virus. Drug development in these areas has exploded since the advent of Medicare Part D in 2006, and the drug benefit has not kept pace with rising costs of new therapies.
Potential solutions featured in the summary include:
· Reducing specialty-tier drug costs by increasing the cost of lower-tier drugs.
· Finding ways to more evenly distribute drug costs, thus taking some of the burden off Medicare Part D enrollees.
· Improving benefit design, and limiting out-of-pocket expenses to a defined monthly minimum.
· Ensuring that at least one specialty drug in each therapeutic class is on a non-specialty tier.
· Putting more focus on value-based design.
The roundtable was associated with an invitation for policy proposals and case studies that were published in a special supplement to AJMC, which can be found by clicking here.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More